Search results
22 maj 2023 · Bullous systemic lupus erythematosus (BSLE) is a rare manifestation of systemic lupus erythematosus. It has clinical and histological features that may lead to misdiagnosis and delayed treatment of this easily treatable condition.
Bullous systemic lupus erythematosus (BSLE) is a rare cutaneous complication of systemic lupus ery-thematosus (SLE). It is a heterogeneous disease that is caused by autoantibodies to the dermoepidermal junction, mainly type VII collagen.
Of note, the 2019 recommendations counted a total of 33 recommendations belonging to 4 domains (goals of treatment, general principles of treatment, specific manifestations and comorbidities). The current update aligns with the EULAR SOPs to include a maximum 15 bullet point statements. To this end,
8 lis 2023 · Bullous SLE is rare blistering disorder characterized by subepidermal blisters. We, hereby, present a case of bullous SLE in a 24-year-old female who responded well to systemic glucocorticoids, mycophenolate mofetil, and dapsone.
31 paź 2014 · Bullous systemic lupus erythematosus (BSLE) is a rare cutaneous complication of systemic lupus erythematosus (SLE). It is a heterogeneous disease that is caused by autoantibodies to the dermoepidermal junction, mainly type VII collagen.
Bullous systemic lupus erythematosus (BSLE) is a rare cutaneous complication of systemic lupus erythematosus (SLE). It is a heterogeneous disease that is caused by autoantibodies to the dermoepidermal junction, mainly type VII collagen.
26 paź 2023 · A core tenet of drug treatment for systemic lupus erythematosus is that treatment with an antimalarial (usually hydroxychloroquine) is recommended for all patients unless contraindicated.
